CoChat

UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo

Open access
Christoph, Sandra, DeRyckere, Deborah, Schlegel, Jennifer, Frazer, J. Kimble, Batchelor, Lance A., Trakhimets, Alesia Y., Sather, Susan, Hunter, Debra M., Cummings, Christopher T., Liu, Jing, Yang, Chao, Kireev, Dmitri, Simpson, Catherine, Norris-Drouin, Jacqueline, Hull-Ryde, Emily A., Janzen, William P., Johnson, Gary L., Wang, Xiaodong, Frye, Stephen V., Earp, H. Shelton, Graham, Douglas K. · 2013 · Molecular Cancer Therapeutics
Cited by 72

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Although survival rates have improved, patients with certain biologic subtypes still have suboptimal outcomes. Current chemotherapeutic regimens are associated with short- and long-term toxicities and novel, less toxic therapeutic strategies are needed. Mer receptor tyrosine kinase is ectopically expressed in ALL patient samples and cell lines. Inhibition of Mer expression reduces prosurvival signaling, increases chemosensitivity, and delays development of leukemia in vivo, suggesting that Mer tyrosine kinase inhibitors are excellent candidates for targeted therapies. Brain and spinal tumors are the second most common malignancies in childhood. Multiple chemotherapy approaches and radiotherapies have been attempted, yet overall survival remains dismal. Mer is also abnormally expressed in atypical teratoid/rhabdoid tumors (AT/RT), providing a rationale for targeting Mer as a therapeutic strategy. We have previously described UNC569, the first small-molecule Mer inhibitor. This article describes the biochemical and biologic effects of UNC569 in ALL and AT/RT. UNC569 inhibited Mer activation and downstream signaling through ERK1/2 and AKT, determined by Western blot analysis. Treatment with UNC569 reduced proliferation/survival in liquid culture, decreased colony formation in methylcellulose/soft agar, and increased sensitivity to cytotoxic chemotherapies. MYC transgenic zebrafish with T-ALL were treated with UNC569 (4 μmol/L for two weeks). Fluorescence was quantified as indicator of the distribution of lymphoblasts, which express Mer and enhanced GFP. UNC569 induced more than 50% reduction in tumor burden compared with vehicle- and mock-treated fish. These data support further development of Mer inhibitors as effective therapies in ALL and AT/RT. Mol Cancer Ther; 12(11); 2367–77. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-13-0040

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 72

Metadata

Authors
Christoph, S., DeRyckere, D., Schlegel, J., Frazer, J. K., Batchelor, L. A., Trakhimets, A. Y., Sather, S., Hunter, D. M., Cummings, C. T., Liu, J., Yang, C., Kireev, D., Simpson, C., Norris-Drouin, J., Hull-Ryde, E. A., Janzen, W. P., Johnson, G. L., Wang, X., Frye, S. V., Earp, H. S., & Graham, D. K.
Venue
Molecular Cancer Therapeutics
Published
2013-11-01
Volume
12
Issue
11
Pages
2367-2377
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W1976711842
Cited by
72
References
1
FWCI
6.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0040
The paper
Christoph, S., DeRyckere, D., Schlegel, J., Frazer, J. K., Batchelor, L. A., Trakhimets, A. Y., Sather, S., Hunter, D. M., Cummings, C. T., Liu, J., Yang, C., Kireev, D., Simpson, C., Norris-Drouin, J., Hull-Ryde, E. A., Janzen, W. P., Johnson, G. L., Wang, X., Frye, S. V., . . . Graham, D. K. (2013). UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.